Phase II/III

July 2005
Applied Clinical Trials;Jul2005, Vol. 14 Issue 7, p16
Academic Journal
Provides information related to latest phase II/III clinical trials. Initiation of a trial for an inhalable form of treprostinil for pulmonary hypertension by Lung Rx; Efficacy of Fibrillex at improving symptoms of Amylois A Amyloidosis, based on Neurochem Inc.'s trial.


Related Articles

  • Tafamidis Slows Fatal Fibril Disease's March.  // Bioworld Week;7/27/2009, Vol. 17 Issue 30, p3 

    The article reports on the result of the Phase II/III trial of FoldRx Pharmaceuticals Inc.'s tafamidis. It notes that the drug shows significant effect, halting disease progression and reducing the burden of disease in patients with transthyretin (TTR) amyloid polyneuropathy (ATTR-RN), a fatal...

  • Phase II.  // Applied Clinical Trials;Jul2005, Vol. 14 Issue 7, p16 

    Provides information related to latest phase II clinical trials. Extension of trial enrollment for Centocor Inc.'s CNTO 1275 for Crohn's disease; Initiation of a trial for OncoVEX, drug developed by BioVEX Ltd. for malignant melanoma tumors; Completion of a trial of SPRC-AB01 for chronic...

  • Other trials.  // Applied Clinical Trials;Jul2005, Vol. 14 Issue 7, p18 

    Provides information related to recent clinical trials in the U.S. Initiation of trials for a tuberculosis drug from the Global Alliance for TB Drug Development; Benefit of endovascular aneurysm repair for low-risk patients; Recommendation by the Food and Drug Administration for Merck & Co. Inc....

  • Treatment of Gastric Ulcer. Juhl, Erik; Tygstrup, Niels; Christensen, Erik // American Journal of Gastroenterology;Mar1978 Part 1, Vol. 69 Issue 3, p272 

    Twenty-nine randomized clinical trials (RCTs) from the decade 1964-74 evaluating treatments of gastric ulcer have been analyzed. None of them fulfilled all criteria for an ideal RCT. The most frequent shortcomings were: short treatment or follow-up periods, incomplete description of the patients...

  • Comparative Study on the Bioequivalence of Two Different Gabapentin Formulations: A randomised, two-period, two-sequence, crossover clinical trial in healthy volunteers. Almeida, Susana; Filipe, Augusto; Almeida, Ana; Antonijoan, Rosa; GarcĂ­a-Gea, Consuelo; Gich, Ignasi; Barbanoj, Manuel; Caturla, Maria Cruz // Drug Research / Arzneimittel-Forschung (Editio Cantor Verlag fur;Feb2006, Vol. 56 Issue 2, p59 

    The bioequivalence of two capsule formulations containing 400 mg gabapentin (CAS 60142-96-3) was assessed in 24 healthy volunteers in an open, randomised, crossover, 2 periods x 2 sequences, with a minimum washout period of 7 days, single-dose study. Plasma samples were obtained at fixed time...

  • Ann Arbor biotech testing osteoporosis drug. Henderson, Tom // Crain's Detroit Business;3/10/2008, Vol. 24 Issue 10, p25 

    The article offers information regarding the drug trials of VEL0230, being conducted by Velcura Therapeutics Inc. It states that Velcura, an Ann Arbor, Michigan-based biotech heavily funded by federal and state grants since it was founded in 2001, has begun clinical trials of a new drug to fight...

  • Untitled.  // BioWorld Today;6/2/2009, Vol. 20 Issue 104, p13 

    The article reports on Cambridge, Massachusetts-based Mersana Therapeutics Incorporated's Phase I trial for its lead development candidate, XMT-1001. The study revealed that ten of 37 evaluable patients dosed to date showed evidence of stable disease and seven patients had prolonged stable...

  • European Congress of Clinical Microbiology and Infectious Diseases: April 2013.  // BioWorld Insight;5/13/2013, Vol. 21 Issue 20, p21 

    A table is presented which lists status of clinical trials performed by various companies including Pfizer Inc., Tetraphase Pharmaceuticals Inc., and by Trius Therapeutics Inc. elaborated upon during the 23rd European Congress of Clinical Microbiology and Infectious Diseases in April 2013.

  • Patterns and Intensity of Medical Therapy in Patients Undergoing Percutaneous Coronary Intervention. Borden, William B.; Redberg, Rita F.; Mushlin, Alvin I.; Dai, David; Kaltenbach, Lisa A.; Spertus, John A. // JAMA: Journal of the American Medical Association;5/11/2011, Vol. 305 Issue 18, p1882 

    The article discusses a study of the use of optimal medical therapy (OMT) in patients with stable angina undergoing percutaneous coronary intervention (PCI) before and after publication of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) study. The study...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics